Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEL | P19835 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.36 |
| ▸ | FEN1 | P39748 | 5/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781868 | 0.96 | CEL (0.42) | CELALOX5APFEN1OPRL1NOS1 | |
| SCHEMBL3793541 | 0.94 | CEL (0.43) | CELFEN1OPRL1NOS1TDO2 | |
| SCHEMBL3786896 | 0.92 | OPRL1 (0.37) | CELOPRL1NR4A2TSHRALDH1A1 | |
| SCHEMBL3789549 | 0.85 | CEL (0.44) | CELALOX5APFEN1OPRL1HTR2A | |
| SCHEMBL3792040 | 0.81 | CEL (0.48) | CELOPRL1HTR2C | |
| SCHEMBL1068978 | 0.79 | NOS1 (0.41) | NOS3NOS1NOS2ALDH1A1HTR2C | |
| SCHEMBL3783301 | 0.79 | CEL (0.50) | CELOPRL1 | |
| SCHEMBL3790181 | 0.76 | CEL (0.38) | CELALOX5APFEN1HTR2AHTR2C | |
| SCHEMBL3794742 | 0.75 | OPRL1 (0.41) | CELOPRL1TSHRHTR2AHTR2C | |
| SCHEMBL5743128 | 0.75 | TDO2 (0.38) | CELFEN1NOS1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CEL 887/4885ALOX5AP 2385/4885FEN1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.